Facing a federal advisory committee in legal limbo, a coalition of major U.S. medical societies published independent seasonal vaccine guidance for COVID-19, influenza, and RSV as families prepare for the 2026-2027 respiratory virus season. The collaborative effort fills a guidance void following court battles over federal vaccine policy.
Traditionally, the Centers for Disease Control and Prevention and its vaccine advisory committee have issued guidance. But the vaccine advisory committee is in legal limbo after a federal judge ruled in March that Health Secretary Robert Kennedy Jr. unlawfully altered vaccine policy and improperly reconstituted the group. To fill the information void, the Vaccine Integrity Project at the University of Minnesota’s Center for Infectious Disease Research and Policy and the American Medical Association published the results of their independent evidence review of the influenza, COVID-19, and RSV vaccines in JAMA, as detailed by CIDRAP.
Medical Societies Step In to Fill Federal Vaccine Void
During a press briefing on the evidence reviews, four of the country’s major medical organizations—the American Academy of Family Physicians, the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, and the Infectious Diseases Society of America—provided their vaccine recommendations for the 2026-27 respiratory illness season.
Bruce Gellin, MD, MPH, chair of the VIP Board of Advisors, emphasized during the briefing that Americans are hearing conflicting messages about vaccines right now, and it’s understandable that people are asking whom they should trust
while encouraging the public to look closely at the process behind the development of these recommendations.
Trump Administration Executive Action Stirs Debate Over Childhood Routine Immunizations
Simultaneously, a separate policy development has added administrative complexity for families with school-aged children. As reported by Yahoo Noticias, a decree signed by President Donald Trump seeks to reduce the number of routine vaccines received by American children and, in some instances, reformulate and space them out.
Medical professionals quickly criticized the approach. Dr. Andrew Racine, president of the American Academy of Pediatrics, stated that the policy planteado en el decreto de Trump perjudicaría a las familias en lugar de ayudarlas
and added that the announcement introduces unnecessary uncertainty, fear, and confusion.
Insurance Coverage and Legal Challenges Lie Ahead
Despite the administrative changes, experts note that immediate practical effects on families will likely take months or years to materialize. Insurers including Blue Cross Blue Shield and CVS indicated they were reviewing the presidential decree but planned to continue covering CDC-recommended pediatric vaccines without copagos in the near term. Furthermore, federal programs such as Vaccines for Children remain bound by statutory guidelines tied to the CDC advisory committee.
Legal challenges are expected. Dr. Dorit Reiss, a professor at the University of California in San Francisco and an expert on vaccine legislation, pointed out that executive orders do not replace statutory congressional procedures.
“Varias leyes del Congreso otorgan la facultad de emitir estas recomendaciones al Comité Asesor sobre Prácticas de Inmunización [de los CDC], sujeto a la aprobación o el rechazo del director de los CDC.”
In response, a White House official defended the administration’s stance, stating that lo que hace este decreto en particular es reconocer, en nombre del presidente, el estándar científico de referencia para el Gobierno de Estados Unidos. Esto es independiente de cualquier otro proceso de comités
.
Worth a look